[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332342-105":59,"doc-detail-332342-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-impact-of-baseline-health-factors-on-second-primary-cancer-risk-after-radiotherapy-for-prostate-cancer-original-article","The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer - Original article","","Purpose: Lifestyle factors are often omitted when evaluating second primary cancers (SPCs) after external beam radiotherapy (EBRT) because of data limitations. This study examined associations between smoking, comorbidities, and SPC risks in EBRT-treated patients with localized prostate cancer. Patients & Methods: 1,883 survivors aged 50–79 were analyzed using registry-linked SPC and survival data with a 12-month latency period. Cox regression and competing-risk analyses estimated cumulative incidences. Results: Overall SPC risk increased (SIR 1.21), with higher pelvis SPC (SIR 1.46) and non-pelvis SPC (SIR 1.18). Smoking related to pelvic and non-pelvic SPCs; higher CCI, cardiovascular disease, and COPD associated with non-pelvis SPC. Interpretation: Comorbidities may explain excess non-pelvis SPC risk, but not excess pelvis SPC risk.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-impact-of-baseline-health-factors-on-second-primary-cancer-risk-after-radiotherapy-for-prostate-cancer-original-article/332342/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-impact-of-baseline-health-factors-on-second-primary-cancer-risk-after-radiotherapy-for-prostate-cancer-original-article/332342.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal regarding SPC risk after EBRT?","Question",{"text":112,"@type":113},"To assess second primary cancer risk after EBRT for localized prostate cancer while considering lifestyle-related factors, especially smoking status at treatment time and comorbidities.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many prostate cancer survivors were included and how was follow-up handled?",{"text":117,"@type":113},"The study included 1,883 survivors aged 50–79 treated between 2006 and 2013, using Netherlands Cancer Registry data with a 12-month latency period.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were associated with increased non-pelvis SPC risk?",{"text":121,"@type":113},"Charlson comorbidity index (CCI) ≥ 1, cardiovascular disease, and COPD were significantly associated with non-pelvis SPC risk.",{"name":123,"@type":110,"acceptedAnswer":124},"What did the interpretation conclude about comorbidities and different SPC locations?",{"text":125,"@type":113},"Comorbidities in the EBRT-treated population may be relevant for the excess non-pelvis SPC risk, but not for excess pelvis SPC risk.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},332342,1790472824,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ORIGINAL ARTICLE  \nTheimpactofbaselinehealthfactorson secondprimarycancer riskafter radiotherapy for prostate cancer  \nMarie-Christina Jahreißa, Luca Incroccia, Katja K.H. Abenb,c, Kim C. deVriesa, Mischa Hoogemana, Maartje J. Hooningd, and Wilma D. Heemsbergena  \na Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; bDepartment of Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands; c Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands; dDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands  \nABSTRACT  \nPurpose: In evaluating second primary cancers (SPCs) following External Beam Radiotherapy (EBRT), the role of lifestyle factors is frequently not considered due to data limitations. We investigated the association between smoking, comorbidities, and SPC risks within EBRT-treated patients for localized prostate cancer (PCa) .  \nPatients & Methods: The study included 1,883 PCa survivors aged 50–79, treated between 2006 and 2013, with intensity-modulated radiotherapy (IMRT) or three-dimensional conformal radiotherapy (3DCRT). Clinical data were combined with SPC and survival data from the Netherlands Cancer Registry with a 12-month latency period. Standardized Incidence Ratios (SIRs) were calculated comparing the EBRT cohort with the general Dutch population. To explore the effect of patient and treatment characteristics on SPCswe conducted a Cox regression analysis. Lastly, we estimated cumulative incidences of developing solid SPC, pelvis SPC, and non-pelvis SPC using a competing risk analysis.  \nResults: Significantly increased SIRs were observed for all SPC (SIR = 1.21, 95% confidence interval [CI]: 1.08–1.34), pelvis SPC (SIR = 1.46, 95% CI: 1.18–1.78), and non-pelvis SPC (SIR = 1.18, 95% CI [1.04–1.34]) . Smoking status was significantly associated with pelvic and non-pelvic SPCs. Charlson comorbidity index (CCI) ≥ 1 (Hazard Ratio [HR] = 1.45, 95% CI: 1.10–1.91), cardiovascular disease (HR = 1.41, 95% CI: 1.05–1.88), and chronic obstructive pulmonary disease (COPD) (HR = 1.91, 95% CI: 1.30–2.79) were significantly associated with non-pelvis SPC. The proportion of active smoking numbers in the cohort was similar to the general population.  \nInterpretation: We conclude that the presence of comorbidities in the EBRT population might be a relevant factor in observed excess non-pelvis SPC risk, but not for excess pelvis SPC risk.  \nARTICLE HISTORY  \nReceived 26 October 2023 Accepted 24 April 2024 Published 30 June 2024  \nKEYWORDS  \nComorbidities; smoking; second primary cancer; prostate cancer; radiotherapy  \nIntroduction  \nThe development of a Second Primary Cancer (SPC) represents a multifaceted process influenced by a complex interplay of genetic, environmental, lifestyle, and treatment-related factors [1] . For prostate cancer (PCa) survivors specifically, significant advances in the detection and treatment have led to high overall survival rates [2]. Consequently, the consideration of adverse events such as the development of a radiation-induced SPC has become increasingly relevant.  \nOne of the main treatment approaches for localized PCa patients is External Beam Radiotherapy (EBRT). EBRT particularly is the preferred choice of treatment for patients who may not be suitable candidates for radical prostatectomy due to physical fitness constraints [3, 4] . Furthermore, recent advances in the field of EBRT have contributed to its growing popularity, driven by the advantages it offers, such as reduced risk of urinary  \nincontinence and diminished chances of erectile dysfunction when contrasted with radical prostatectomy [5] .  \nStudies, however, have reported elevated risk for SPC development after EBRT as opposed to alternative treatments, such as radical prostatectomy [6 –10] . This heightened risk can be attributed to the well-known fact that DNA damage in healthy tissue exposed to (very) low to intermedi","cbCaiaB6zBQUnoJm","https://ap.wps.com/l/cbCaiaB6zBQUnoJm","pdf",406710,"English","# Abstract\n## Patients & Methods\n## Results\n## Interpretation\n# Introduction\n## EBRT and SPC risk background\n## Study objective\n# Method\n## Study design and participants","[{\"question\":\"What was the study’s main goal regarding SPC risk after EBRT?\",\"answer\":\"To assess second primary cancer risk after EBRT for localized prostate cancer while considering lifestyle-related factors, especially smoking status at treatment time and comorbidities.\"},{\"question\":\"How many prostate cancer survivors were included and how was follow-up handled?\",\"answer\":\"The study included 1,883 survivors aged 50–79 treated between 2006 and 2013, using Netherlands Cancer Registry data with a 12-month latency period.\"},{\"question\":\"Which factors were associated with increased non-pelvis SPC risk?\",\"answer\":\"Charlson comorbidity index (CCI) ≥ 1, cardiovascular disease, and COPD were significantly associated with non-pelvis SPC risk.\"},{\"question\":\"What did the interpretation conclude about comorbidities and different SPC locations?\",\"answer\":\"Comorbidities in the EBRT-treated population may be relevant for the excess non-pelvis SPC risk, but not for excess pelvis SPC risk.\"}]","The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer - Original article | PDF",1789997775,18]